New Alzheimer’s drug could ‘remove’ harmful proteins associated with the disease, experts claim

New Alzheimer’s drug could ‘remove’ harmful proteins linked to degenerative disease, experts claim

Experts welcome a “significant step forward”. Alzheimer’s disease Treatment after drugs have been found to remove harmful proteins associated with the condition.

Tau is one of the major proteins associated with the disease, forming ‘tangles’ that interfere with brain cells and impair the ability to think and remember.

For the first time, researchers were able to reduce protein levels with a “gene-silencing” approach.

university college team London We studied 46 patients with mild Alzheimer’s disease and high levels of tau, with a mean age of 66 years.

Most people received three injections of a drug called BIIB080 into their nervous system, and the rest were placebos.

Experts have hailed a

Experts have hailed a “significant advance” in the quest for a cure for Alzheimer’s disease after the discovery of a drug that removes harmful proteins associated with Alzheimer’s disease. [File image]

The drug is designed to prevent protein production by “silencing” the genes that code for proteins.

The journal Nature Medicine reported that people receiving the highest dose had a 50% reduction in central nervous system tau levels after 24 weeks, with no serious side effects.

Dr Susan Kohlhaas, Executive Director of Research and Partnerships, Alzheimer’s Research UK, said:

“In this early-stage trial, researchers used a new type of approach to have drugs “switch off” a gene called the MAPT gene, which makes the tau protein.

“This lowers tau levels in patients with mild Alzheimer’s disease, suggesting that the drug has hit the right target. The drug appears to be safe even at the doses given in this small trial. I saw.

The drug is designed to prevent protein production by “silencing” the genes that code for proteins. [File image]

“These early findings are promising, but there is still much work to be done. It’s in progress.

“A Phase 2 trial of this drug is now aiming to enroll 700 people, confirming that the study will be replicated in the next trial, confirming that this therapeutic approach will reach the clinic. Larger studies are essential.

“It’s a very exciting time in dementia research as each new discovery brings us closer to new treatments. Research like this can make a real difference in the lives of people affected by dementia.” shows how important clinical trials are.

“With more studies like this, research will pave the way for treatments.”

https://www.dailymail.co.uk/health/article-12008987/New-Alzheimers-drug-remove-harmful-proteins-associated-disease-experts-claim.html?ns_mchannel=rss&ns_campaign=1490&ito=1490 New Alzheimer’s drug could ‘remove’ harmful proteins associated with the disease, experts claim

Exit mobile version